Pamela N. Münster
Interdisciplinary Oncology Program
H. Lee Moffitt Cancer Center and Research Institute
12901 Magnolia Drive
Tampa
USA
Name/email consistency: high
- Arzoxifene: the development and clinical outcome of an ideal SERM. Munster, P.N. Expert. Opin. Investig. Drugs (2006)
- In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Marchion, D.C., Bicaku, E., Daud, A.I., Sullivan, D.M., Munster, P.N. Mol. Cancer Ther. (2005)
- Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Münster, P.N., Marchion, D.C., Basso, A.D., Rosen, N. Cancer Res. (2002)
- Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001. Münster, P.N., Basso, A., Solit, D., Norton, L., Rosen, N. Clin. Cancer Res. (2001)
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Munster, P.N., Troso-Sandoval, T., Rosen, N., Rifkind, R., Marks, P.A., Richon, V.M. Cancer Res. (2001)
- Predictive factor for the response to adjuvant therapy with emphasis in breast cancer. Munster, P.N., Norton, L. Breast Cancer Res. (2001)